Cell proliferation assay, IC50 assay, and drug response assay

XZ Xiaoquan Zhu
CC Chao Chen
DW Dong Wei
YX Yong Xu
SL Siying Liang
WJ Wenlong Jia
JL Jian Li
YQ Yanchun Qu
JZ Jianpo Zhai
YZ Yaoguang Zhang
PW Pengjie Wu
QH Qiang Hao
LZ Linlin Zhang
WZ Wei Zhang
XY Xinyu Yang
LP Lin Pan
RQ Ruomei Qi
YL Yao Li
FW Feiliang Wang
RY Rui Yi
ZY Ze Yang
JW Jianye Wang
YZ Yanyang Zhao
WZ Wilbert Zwart
request Request a Protocol
ask Ask a question
Favorite

For growth curve of NIH3T3 and RWPE-1 cell lines, indicated cells were seeded at 3000 cells per well in a 96-well plate in quadruplicate, treating with increasing drug concentrations for 48 hr. Foretinib (#A2974) was purchased from ApexBio. MK2206 (#HY-10358) was purchased from MCE. The viability rate of each cell line treated with different drug concentrations was normalized to that of the corresponding untreated cells. The in vitro half-maximal inhibitory concentration (IC50) values were determined using Orange 8.0 software and dose–response curves were plotted with package drc in R environment. For proliferation assay of RWPE-1, PC3, or LNCaP cells, indicated cells were seeded at 3000 cells per well in a 96-well plate in quadruplicate for 6 d (RWPE-1), 8 d (PC3), and 9 d (LNCaP), respectively. The viability of cells was determined using a Celltiter-Glo assay (Promega) on INFINITE 200 Pro multimode reader (TECAN). For drug response assay, NIH3T3 cells stably expressing the FOXP2 and FOXP2-CPED1, respectively were suspended in 0.4% soft agar at 3000 cells (cell suspension in complete growth medium mixed with 2× DMEM, 20% FBS, and 1.2% agar at a 1:1:1 dilution) with indicated drug concentrations. Each cell line was plated in quadruplicate. The medium with indicated drug concentration was changed every 4 d and incubated for 4 wk. The colony counting was performed using a Nikon microscope and representative images were then acquired. RWPE-1 cells stably expressing the FOXP2 and FOXP2-CPED1, respectively, were plated at a density of 3000 cells per well in triplicate in a 6-well plate for 12 d with indicated drug concentrations, then fixed with 4% paraformaldehyde solution for 10 min and subsequently stained with 0.05% crystal violet.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A